<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891653</url>
  </required_header>
  <id_info>
    <org_study_id>QF-BR790-101</org_study_id>
    <nct_id>NCT04891653</nct_id>
  </id_info>
  <brief_title>A Phase I Study of BR790 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and Efficacy of BR790 Monotherapy in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the safety and tolerability of BR790 tablets as an&#xD;
      oral monotherapy in subjects with advanced solid tumors, and to determine dose-limiting&#xD;
      toxicity (DLT), maximum tolerated dose (MTD) and/or recommended phase II clinical trial dose&#xD;
      (RP2D) .The study is divided into two phases: dose escalation phase and dose expansion phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>up to 32 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD)</measure>
    <time_frame>up to 32 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>recommended phase II clinical study dose (RP2D)</measure>
    <time_frame>up to 32 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 32 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 32 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 32 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pERK</measure>
    <time_frame>up to 32 day</time_frame>
    <description>the level of pERK in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>through study completion, an average of 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>5-65mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR790</intervention_name>
    <description>Subjects will receive oral administration of BR790.</description>
    <arm_group_label>5-65mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign informed consent voluntarily.&#xD;
&#xD;
          -  Age ≥18 and ≤75 years old.&#xD;
&#xD;
          -  Subjects with advanced solid tumors diagnosed by histology or cytology，whose desease&#xD;
             progressed after standard treatment or have no standard treatment.&#xD;
&#xD;
          -  Had at least one measurable lesion.&#xD;
&#xD;
          -  ECOG≤1.&#xD;
&#xD;
          -  Expected survival period ≥ 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous treatment with SHP-2 inhibitor.&#xD;
&#xD;
          -  Symptomatic brain metastases.&#xD;
&#xD;
          -  Subjects with thoracic/ascites fluid that need drainage or intervention.&#xD;
&#xD;
          -  Subjects with not enough organ functional reserve at baseline, which met at least one&#xD;
             of the following criteria： ANC&lt;1.5×10^9/L PLT&lt;100×10^9/L Hb&lt;90g/L TBIL&gt;1.5×ULN ALT,&#xD;
             AST&gt;2.5×ULN (without liver metastases) or ALT, AST&gt;5×ULN (with liver metastases), Cr&#xD;
             &gt;1.5×ULN.&#xD;
&#xD;
          -  With uncontrolled severe disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

